Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. Low-ER expression patients are removed?

Breast Journal

Volumn 19, Issue 4, 2013, Pages 357-364

  Milburn, Meghan ^a   Rosman, Martin ^b   Mylander, Charles ^b   Tafra, Lorraine ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ANNE ARUNDEL MEDICAL CENTER   (United States)

Author keywords

breast cancer; immunohistochemistry; oncotype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOTYPE DX; PROTEIN EXPRESSION; RECURRENCE RISK;

BREAST CANCER; IMMUNOHISTOCHEMISTRY; ONCOTYPE;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84879786061     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12126     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, et al,. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. Paik S, Shak S, Tang G, et al,. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
3. Dowsett M, Cuzick J, Wale C, et al,. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with Anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28: 1829-34.
4. Geradts J, Bean SM, Bentley RC, Barry WT,. The Oncotype recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010; 28: 969-77.
5. Genomic Health, Inc. 2011. http://www.genomichealth.com (accessed March 26, 2013).
6. Sparano JA, Paik S,. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-8.
7. Paik S, Tang G, Shak S, et al,. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-34.
8. Kelly CM, Warner E, Tsoi DT, et al,. Review of the clinical studies using the 21-gene assay. Oncologist 2010; 15: 447-56.
9. Habel LA, Shak S, Jacobs MK, et al,. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25.
10. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (version 1.2012). National Comprehensive Cancer Network, 2012, Http://www.nccn.org
11. Lo SS, Mumby PB, Norton J, et al,. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671-6.
12. Rosman M, Mylander WC, Tafra L,. What is the value of the 21-gene recurrence score in HER2-negative patients? J Clin Oncol 2010; 28: e647.
13. Dowsett M, Allred C, Know J, et al,. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008; 26: 1059-65.
14. Goldstein LJ, Gray R, Badve S, et al,. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 4063-71.
15. Cronin M, Sangli C, Liu M, et al,. Analytic validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007; 53: 1084-91.
16. Flanagan MB, Dabbs DJ, Brufsky AM, et al,. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008; 21: 1255-61.
17. Grimes M, Coad J, Oliviero B, et al,. Comparison of Oncotype-DX recurrence score and standard immunohistochemical prognostic markers (abstract no.131). Mod Pathol 2007; 20 (2 Suppl): 33A.
18. Auerbach J, Kim M, Fineberg S,. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med 2010; 134: 1697-701.
19. Cuzick J, Dowsett M, Pineda S, et al,. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011; 29: 4273-8.
20. Wolf I, Ben-Baruch N, Shapira-Frommer R, et al,. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Am Cancer Soc 2007; 112: 731-6.
21. Fisher B, Jeong J, Bryant J, et al,. Treatment of lymph-node-negative, oesterogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858-68.